Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Gefitinib"" wg kryterium: Temat


Tytuł :
The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies.
Autorzy :
Ye J; Department of Surgery, Chongqing Yongchuan Health Center for Women and Children.
Tian T; Department of General Surgery, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Chen X; Department of General Surgery, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Oct 23; Vol. 99 (43), pp. e22613.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Breast Neoplasms/*drug therapy
Gefitinib/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Gefitinib/adverse effects ; Humans ; Middle Aged ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry.
Autorzy :
Wang C; Department of Pharmacy, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Zhang J; Phase I Clinical Trial Ward/Department of Pharmacy, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Zhou S; Department of Pharmacy, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Yu L; Department of Function Examination, the Children's Hospital of Jiangxi Province, Nanchang, Jiangxi, China.
Han F; Phase I Clinical Trial Ward/Department of Pharmacy, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Ling R; Department of Pathology, Zhejiang Jinhua Guangfu Hospital, Jinhua, Zhejiang, China.
Ling J; Department of Pharmacy, Zhejiang Jinhua Guangfu Hospital, Jinhua, Zhejiang, China.; Department of Pharmaceutical Analysis, School of Pharmacy, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jul 23; Vol. 15 (7), pp. e0236523. Date of Electronic Publication: 2020 Jul 23 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*blood
Gefitinib/*chemistry
Lung Neoplasms/*blood
Carcinoma, Non-Small-Cell Lung/drug therapy ; Chromatography, High Pressure Liquid ; Gefitinib/blood ; Gefitinib/metabolism ; Gefitinib/therapeutic use ; Humans ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
Autorzy :
Tan WK; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Tan ARY; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Sivanandam P; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Goh EJH; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Yap ZP; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Saburulla NF; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Austin-Muttitt K; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Mullins JGL; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.).
Lau AJ; Department of Pharmacy, Faculty of Science (W.K.T., A.R.Y.T., P.S., E.J.H.G., Z.P.Y., N.F.S., A.J.L.) and Department of Pharmacology, Yong Loo Lin School of Medicine (A.J.L.), National University of Singapore, Singapore, Singapore; and Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom (K.A.-M., J.G.L.M.) .
Pokaż więcej
Źródło :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2020 Aug; Vol. 374 (2), pp. 295-307. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Docking Simulation*
Acetamides/*metabolism
Aldehyde Oxidase/*antagonists & inhibitors
Erlotinib Hydrochloride/*pharmacology
Gefitinib/*pharmacology
Liver/*drug effects
Methotrexate/*metabolism
Pyrimidines/*metabolism
Aldehyde Oxidase/chemistry ; Aldehyde Oxidase/metabolism ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/metabolism ; Enzyme Inhibitors/pharmacology ; Erlotinib Hydrochloride/metabolism ; Gefitinib/metabolism ; Humans ; Liver/metabolism ; Protein Conformation
Czasopismo naukowe
Tytuł :
A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Autorzy :
Zhao Q; Department of Traditional Chinese Medicine, First Medical Center, Chinese PLA General Hospital, Beijing.
Sun K; Penglai Traditional Chinese Medicine Hospital, Penglai.
Lei X; Laibin Traditional Chinese Medicine Hospital, Laibin.
Cai L; Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jul 31; Vol. 99 (31), pp. e21490.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*administration & dosage
Lung Neoplasms/*drug therapy
Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Diarrhea/chemically induced ; Disease-Free Survival ; Exanthema/chemically induced ; Female ; Gefitinib/adverse effects ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Progression-Free Survival ; Thrombocytopenia/chemically induced ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC.
Autorzy :
Lu X; aDepartment of Oncology bDepartment of Pulmonary & Critical Care Medicine, Hainan Hospital of PLA General Hospital, Sanya cXinglong Red Cross Hospital of Wanninng, Wanning City, Hainan Province, China.
Li S
Chen W
Zheng D
Li Y
Li F
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jul 17; Vol. 99 (29), pp. e21170.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*standards
Pemetrexed/*standards
Aged ; Antineoplastic Agents/standards ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/standards ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Gefitinib/therapeutic use ; Humans ; Male ; Pemetrexed/therapeutic use ; Progression-Free Survival
Czasopismo naukowe
Tytuł :
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
Autorzy :
Kawamura T; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Imamura CK; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kenmotsu H; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Taira T; Division of Medical Oncology, Sagara Hospital, 3-31 Matsubara-cho, Kagoshima City, Kagoshima, 892-0833, Japan.
Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Nakashima K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Naito T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Mushiroda T; Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan.
Tanigawara Y; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. .
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Mar; Vol. 85 (3), pp. 605-614. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Chemical and Drug Induced Liver Injury/*etiology
Gefitinib/*adverse effects
Gefitinib/*therapeutic use
Liver/*drug effects
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacokinetics ; Area Under Curve ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/metabolism ; Chemical and Drug Induced Liver Injury/genetics ; Chemical and Drug Induced Liver Injury/metabolism ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/genetics ; Drug-Related Side Effects and Adverse Reactions/metabolism ; ErbB Receptors/genetics ; Female ; Gefitinib/pharmacokinetics ; Humans ; Liver/metabolism ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Autorzy :
Cheng M
Yu X; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Lu K
Xie L
Wang L
Meng F; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Han X
Chen X
Liu J; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Xiong Y
Jin J; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Feb 13; Vol. 63 (3), pp. 1216-1232. Date of Electronic Publication: 2020 Jan 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gefitinib/*analogs & derivatives
Gefitinib/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Adaptor Proteins, Signal Transducing/metabolism ; Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Design ; Drug Discovery ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Gefitinib/metabolism ; Gefitinib/pharmacokinetics ; Humans ; Male ; Mice ; Mutation ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/pharmacokinetics ; Proteolysis ; Signal Transduction/drug effects ; Von Hippel-Lindau Tumor Suppressor Protein/metabolism
Czasopismo naukowe
Tytuł :
Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice.
Autorzy :
Oda S; Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine.
Miyazaki N; Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine.
Tsuneyama K; Department of Molecular and Environmental Pathology, Institute of Health Biosciences, Tokushima University Graduate School.
Yokoi T; Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine.
Pokaż więcej
Źródło :
The Journal of toxicological sciences [J Toxicol Sci] 2020; Vol. 45 (8), pp. 493-502.
Typ publikacji :
Journal Article
MeSH Terms :
Oxidative Stress*
Chemical and Drug Induced Liver Injury/*etiology
Chemical and Drug Induced Liver Injury/*metabolism
Gefitinib/*adverse effects
Gefitinib/*toxicity
Glutathione/*deficiency
Glutathione/*metabolism
Liver/*metabolism
Liver/*pathology
Protein Kinase Inhibitors/*adverse effects
Protein Kinase Inhibitors/*toxicity
Animals ; Buthionine Sulfoximine/pharmacology ; Chemical and Drug Induced Liver Injury/pathology ; Cytochrome P-450 CYP3A/physiology ; Disease Progression ; Gefitinib/metabolism ; Glutathione/physiology ; Mice, Inbred C57BL ; Protein Kinase Inhibitors/metabolism
Czasopismo naukowe
Tytuł :
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer.
Autorzy :
Noronha V; Tata Memorial Center, Mumbai, India.
Patil VM; Tata Memorial Center, Mumbai, India.
Joshi A; Tata Memorial Center, Mumbai, India.
Menon N; Tata Memorial Center, Mumbai, India.
Chougule A; Tata Memorial Center, Mumbai, India.
Mahajan A; Tata Memorial Center, Mumbai, India.
Janu A; Tata Memorial Center, Mumbai, India.
Purandare N; Tata Memorial Center, Mumbai, India.
Kumar R; Tata Memorial Center, Mumbai, India.
More S; Tata Memorial Center, Mumbai, India.
Goud S; Tata Memorial Center, Mumbai, India.
Kadam N; Gunvati J. Kapoor Medical Relief Charitable Foundation, Mumbai, India.
Daware N; Gunvati J. Kapoor Medical Relief Charitable Foundation, Mumbai, India.
Bhattacharjee A; Tata Memorial Center, Mumbai, India.
Shah S; Tata Memorial Center, Mumbai, India.
Yadav A; Tata Memorial Center, Mumbai, India.
Trivedi V; Tata Memorial Center, Mumbai, India.
Behel V; Tata Memorial Center, Mumbai, India.
Dutt A; Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.
Banavali SD; Tata Memorial Center, Mumbai, India.
Prabhash K; Tata Memorial Center, Mumbai, India.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Jan 10; Vol. 38 (2), pp. 124-136. Date of Electronic Publication: 2019 Aug 14.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Female ; Gefitinib/administration & dosage ; Gefitinib/adverse effects ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Mutation ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Quality of Life
Czasopismo naukowe
Tytuł :
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Autorzy :
Hosomi Y; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Morita S; Kyoto University Graduate School of Medicine, Kyoto, Japan.
Sugawara S; Sendai Kousei Hospital, Sendai, Japan.
Kato T; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Fukuhara T; Miyagi Cancer Center, Natori, Japan.
Gemma A; Nippon Medical School, Tokyo, Japan.
Takahashi K; Juntendo University Graduate School of Medicine, Tokyo, Japan.
Fujita Y; Asahikawa Medical Center, Asahikawa, Japan.
Harada T; Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.
Minato K; Gunma Prefectural Cancer Center, Ota, Japan.
Takamura K; Obihiro Kosei General Hospital, Obihiro, Japan.
Hagiwara K; Jichi Medical University, Shimotsuke, Japan.
Kobayashi K; Saitama Medical University, Hidaka, Japan.
Nukiwa T; Tohoku University, Sendai, Japan.
Inoue A; Tohoku University School of Medicine, Sendai, Japan.
Pokaż więcej
Corporate Authors :
North-East Japan Study Group
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Jan 10; Vol. 38 (2), pp. 115-123. Date of Electronic Publication: 2019 Nov 04.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Female ; Gefitinib/administration & dosage ; Gefitinib/adverse effects ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Mutation ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Quality of Life ; Survival Rate
Czasopismo naukowe
Tytuł :
Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction.
Autorzy :
Kato R; Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences.
Ijiri Y; Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences.
Hayashi T; Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences.
Uetrecht J; Department of Pharmaceutical Scinces, Faculty of Pharmacy, University of Toronto, Canada.
Pokaż więcej
Źródło :
The Journal of toxicological sciences [J Toxicol Sci] 2020; Vol. 45 (11), pp. 673-680.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatocytes*
Culture Media/*adverse effects
Gefitinib/*adverse effects
Inflammasomes/*immunology
Macrophage Activation/*drug effects
Protein Kinase Inhibitors/*adverse effects
THP-1 Cells/*immunology
Alarmins/metabolism ; Caspase 1/metabolism ; Cell Line ; Gefitinib/metabolism ; HMGB1 Protein/metabolism ; Humans ; Interleukin-1beta/metabolism ; Protein Kinase Inhibitors/metabolism ; Quinones/adverse effects ; Quinones/metabolism ; THP-1 Cells/metabolism
Czasopismo naukowe
Tytuł :
Reply to T. Tanaka et al and F. Liang.
Autorzy :
Noronha V; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Patil VM; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Joshi A; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Menon N; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Chougule A; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Prabhash K; Vanita Noronha, MBBS, MD, DM; Vijay M. Patil, MBBS, MD, DM; Amit Joshi, MBBS, MD, DM; Nandini Menon, MBBS, MD, DNB; Anuradha Chougule, PhD; and Kumar Prabhash, MBBS, MD, DM, Homi Bhabha National Institute (HBNI); and Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Mar 10; Vol. 38 (8), pp. 844-846. Date of Electronic Publication: 2020 Jan 02.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Gefitinib*
Lung Neoplasms*
Carboplatin ; ErbB Receptors ; Humans ; Pemetrexed
Raport
Tytuł :
Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
Autorzy :
Liang F; Fei Liang, MD, Zhongshan Hospital, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Mar 10; Vol. 38 (8), pp. 844. Date of Electronic Publication: 2020 Jan 02.
Typ publikacji :
Letter; Comment
MeSH Terms :
Gefitinib*
Lung Neoplasms*
Carboplatin ; ErbB Receptors ; Humans ; Models, Statistical ; Pemetrexed
Opinia redakcyjna
Tytuł :
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Autorzy :
Takeuchi S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Hase T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shimizu S; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Ando M; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Hata A; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.; Department of Medical Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kawakami T; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.
Nagase K; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.
Yoshimura K; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.; Department of Data Science, Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima, Japan.
Fujiwara T; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Tanimoto A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Nishiyama A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Arai S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Fukuda K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Katakami N; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.; Department of Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hasegawa Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Ko TK; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore.
Ong ST; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore.; Department of Haematology, Singapore General Hospital, Singapore.; Department of Medical Oncology, National Cancer Centre Singapore, Singapore.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Yano S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Feb; Vol. 111 (2), pp. 561-570. Date of Electronic Publication: 2020 Jan 06.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Bcl-2-Like Protein 11/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*administration & dosage
Lung Neoplasms/*drug therapy
Vorinostat/*administration & dosage
Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Drug Administration Schedule ; ErbB Receptors/genetics ; Female ; Gefitinib/pharmacokinetics ; Humans ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Mutation ; Sequence Deletion ; Survival Analysis ; Treatment Outcome ; Vorinostat/pharmacokinetics
Czasopismo naukowe
Tytuł :
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Autorzy :
Leighl NB; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Karaseva N; City Clinical Oncology Dispensary, St. Petersburg, Russia.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Gray JE; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Hovey T; PHASTAR, London, UK.
Walding A; AstraZeneca R&D, Cambridge, UK.
Rydén A; AstraZeneca Gothenburg, Mölndal, Sweden.
Novello S; Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Turin, Italy. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Jan; Vol. 125, pp. 49-57. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Patient Reported Outcome Measures*
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Erlotinib Hydrochloride/*therapeutic use
Gefitinib/*therapeutic use
Lung Neoplasms/*drug therapy
Acrylamides/pharmacology ; Aniline Compounds/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carcinoma, Non-Small-Cell Lung/pathology ; Erlotinib Hydrochloride/pharmacology ; Female ; Gefitinib/pharmacology ; Humans ; Lung Neoplasms/pathology ; Male
Czasopismo naukowe
Tytuł :
Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
Autorzy :
Arulananda S; Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute; Department of Medical Oncology, Austin Health; and the School of Cancer Medicine, La Trobe University, Heidelberg, Australia. Electronic address: .
John T; Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute; Department of Medical Oncology, Austin Health; and the School of Cancer Medicine, La Trobe University, Heidelberg, Australia.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Jan; Vol. 15 (1), pp. 12-14.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Gefitinib*
Lung Neoplasms*
Biomarkers ; ErbB Receptors/genetics ; Humans ; Mutation ; Pemetrexed
Opinia redakcyjna
Tytuł :
Tetrandrine Increases the Sensitivity of Human Lung Adenocarcinoma PC14 Cells to Gefitinib by Lysosomal Inhibition.
Autorzy :
Sato E; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Ohta S; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Kawakami K; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Ikeda M; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Takahashi T; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Kobayashi S; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
Nomura M; Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2019 Dec; Vol. 39 (12), pp. 6585-6593.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*metabolism
Benzylisoquinolines/*pharmacology
Gefitinib/*pharmacology
Lung Neoplasms/*metabolism
Lysosomes/*metabolism
Microtubule-Associated Proteins/*metabolism
Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/genetics ; Autophagy ; Benzylisoquinolines/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; ErbB Receptors/genetics ; Gefitinib/chemistry ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lysosomes/drug effects ; Microtubule-Associated Proteins/genetics
Czasopismo naukowe
Tytuł :
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.
Autorzy :
Yoshioka H; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata.
Shimokawa M; Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube.
Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka.
Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto.
Yatabe Y; Department of Pathology and Molecular Genetics, Aichi Cancer Center Hospital, Nagoya.
Okamoto I; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka.
Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo.
Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi.
Hirashima T; Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino.
Atagi S; Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai.
Shibata K; Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka.
Saito H; Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki.
Toyooka S; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama.
Yamamoto N; Internal Medicine III, Wakayama Medical University Hospital, Wakayama.
Nakagawa K; Department of Medical Oncology, Kindai University Hospital, Osaka-Sayama.
Mitsudomi T; Division of Thoracic Surgery, Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec 01; Vol. 30 (12), pp. 1978-1984.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Cisplatin/*administration & dosage
Docetaxel/*administration & dosage
Gefitinib/*administration & dosage
Neoplasm Recurrence, Local/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cisplatin/adverse effects ; Disease-Free Survival ; Docetaxel/adverse effects ; ErbB Receptors/genetics ; Female ; Gefitinib/adverse effects ; Humans ; Japan/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Proportional Hazards Models ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A validated high-performance liquid chromatography-tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study.
Autorzy :
Zhao C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Zheng N; National Drug Clinical Trial Center, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Yang F; National Drug Clinical Trial Center, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Han SY; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Li PP; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Pokaż więcej
Źródło :
Biomedical chromatography : BMC [Biomed Chromatogr] 2019 Nov; Vol. 33 (11), pp. e4638. Date of Electronic Publication: 2019 Aug 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*analysis
Chromatography, High Pressure Liquid/*methods
Gefitinib/*analysis
Lung Neoplasms/*metabolism
Tandem Mass Spectrometry/*methods
Animals ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Female ; Gefitinib/pharmacokinetics ; Heterografts ; Linear Models ; Mice ; Mice, Nude ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Autorzy :
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: .
Cheng Y; Jilin Province Cancer Hospital, Changchun, China.
Zhou J; The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Lu S; Shanghai Chest Hospital, Shanghai, China.
Zhang Y; Zhejiang Cancer Hospital, Hangzhou, China.
Zhao J; Beijing Cancer Hospital, Beijing, China.
Kim DW; Seoul National University Hospital, Seoul, South Korea.
Soo RA; National University Cancer Institute, Singapore.
Kim SW; Asan Medical Center, Seoul, South Korea.
Pan H; Sir Run Run Shaw Hospital, Zhejiang Medical University, Zhejiang, China.
Chen YM; Department of Chest Medicine, Taipei Veteran General Hospital and School of Medicine, Taipei, Taiwan.
Chian CF; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Liu X; Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Tan DSW; National Cancer Center, Singapore.
Bruns R; Biostatistics, Merck KGaA, Darmstadt, Germany.
Straub J; Translational Medicine, Department of Clinical Biomarkers and Companion Diagnostics, Merck KGaA, Darmstadt, Germany.
Johne A; Global Clinical Development, Merck KGaA, Darmstadt, Germany.
Scheele J; Global Clinical Development, Merck KGaA, Darmstadt, Germany.
Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yang JC; National Taiwan University Hospital, Taipei, Taiwan.
Pokaż więcej
Corporate Authors :
INSIGHT Investigators
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2020 Nov; Vol. 8 (11), pp. 1132-1143. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*administration & dosage
Gene Expression Regulation, Neoplastic/*genetics
Lung Neoplasms/*drug therapy
Piperidines/*administration & dosage
Proto-Oncogene Proteins c-met/*genetics
Pyridazines/*administration & dosage
Pyrimidines/*administration & dosage
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/drug effects ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Prognosis ; Proportional Hazards Models ; Risk Assessment ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies